Literature DB >> 21573942

Idiopathic noncirrhotic intrahepatic portal hypertension is associated with sustained ADAMTS13 Deficiency.

Ian Mackie1, C E Eapen, Desley Neil, Andrew S Lawrie, Andrew Chitolie, Jean C Shaw, Elwyn Elias.   

Abstract

BACKGROUND: ADAMTS13 deficiency leading to excess ultralarge von Willebrand factor (VWF) multimers and platelet clumping is typically found in thrombotic thrombocytopenic purpura (a type of thrombotic microangiopathy). Idiopathic noncirrhotic intrahepatic portal hypertension (NCIPH) is a microangiopathy of portal venules associated with significant thrombocytopenia and predisposing gut disorders. AIM: To determine whether the portal microangiopathy in NCIPH is associated with ADAMTS13 deficiency.
METHODS: Plasma levels of ADAMTS13, anti-ADAMTS13 antibodies, and VWF were compared between cases (NCIPH patients) and controls (with chronic liver diseases of other etiology) matched for severity of liver dysfunction. Eighteen NCIPH patients [median (range) MELD score 12 (7-25)] and 25 controls [MELD score 11 (4-26)] were studied.
RESULTS: ADAMTS13 activity was reduced in all 18 NCIPH patients and significantly lower than controls (median, IQR: 12.5%, 5-25% and 59.0%, 44-84%, respectively, P<0.0001) [normal range for plasma ADAMTS13 activity (55-160%)]. ADAMTS13 activity was <5% in 5/18 NCIPH patients (28%) and 0/25 controls (P=0.009). ADAMTS13 antigen levels were also decreased. Sustained low ADAMTS13 levels were seen in four NCIPH patients over 6 weeks to 11 months (highest ADAMTS13 level in each patient: <5%, 6%, 6%, and 25%), despite two patients having MELD score 12. Although nine cases had low titer anti-ADAMTS13 antibodies, there was no significant difference between cases and controls. Abnormally large VWF multimers were observed in 4/11 NCIPH patients (36%) and in 0/22 controls (P=0.008).
CONCLUSIONS: Sustained deficiency of ADAMTS13 appears characteristic of NCIPH, irrespective of severity of liver disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21573942     DOI: 10.1007/s10620-011-1729-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  41 in total

1.  Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP)

Authors:  H E Gerritsen; P L Turecek; H P Schwarz; B Lämmle; M Furlan
Journal:  Thromb Haemost       Date:  1999-11       Impact factor: 5.249

2.  Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies.

Authors:  S C Meyer; I Sulzer; B Lämmle; J A Kremer Hovinga
Journal:  J Thromb Haemost       Date:  2007-04       Impact factor: 5.824

Review 3.  Alteration of protein glycosylation in liver diseases.

Authors:  Bram Blomme; Christophe Van Steenkiste; Nico Callewaert; Hans Van Vlierberghe
Journal:  J Hepatol       Date:  2008-12-27       Impact factor: 25.083

Review 4.  ADAMTS-13 assays in thrombotic thrombocytopenic purpura.

Authors:  F Peyvandi; R Palla; L A Lotta; I Mackie; M A Scully; S J Machin
Journal:  J Thromb Haemost       Date:  2010-01-21       Impact factor: 5.824

5.  Non-cirrhotic intrahepatic portal hypertension: A long term follow-up study.

Authors:  J G Kingham; D A Levison; A G Stansfeld; A M Dawson
Journal:  Q J Med       Date:  1981

6.  ADAMTS13 is expressed in hepatic stellate cells.

Authors:  Wenhua Zhou; Mari Inada; Tai-Ping Lee; Daniel Benten; Sergey Lyubsky; Eric E Bouhassira; Sanjeev Gupta; Han-Mou Tsai
Journal:  Lab Invest       Date:  2005-06       Impact factor: 5.662

7.  Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.

Authors:  Shiv Kumar Sarin; Ashish Kumar; Yogesh Kumar Chawla; Sanjay Saran Baijal; Radha Krishna Dhiman; Wasim Jafri; Laurentius A Lesmana; Debendranath Guha Mazumder; Masao Omata; Huma Qureshi; Rizvi Moattar Raza; Peush Sahni; Puja Sakhuja; Mohammad Salih; Amal Santra; Barjesh Chander Sharma; Praveen Sharma; Gamal Shiha; Jose Sollano
Journal:  Hepatol Int       Date:  2007-09-11       Impact factor: 6.047

8.  N-Glycans of ADAMTS13 modulate its secretion and von Willebrand factor cleaving activity.

Authors:  Wenhua Zhou; Han-Mou Tsai
Journal:  Blood       Date:  2008-11-03       Impact factor: 22.113

9.  Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients.

Authors:  S Hillaire; E Bonte; M-H Denninger; N Casadevall; J-F Cadranel; D Lebrec; D Valla; C Degott
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

10.  ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.

Authors:  Hendrik B Feys; Maria T Canciani; Flora Peyvandi; Hans Deckmyn; Karen Vanhoorelbeke; Pier M Mannucci
Journal:  Br J Haematol       Date:  2007-06-29       Impact factor: 6.998

View more
  15 in total

1.  ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension.

Authors:  Ashish Goel; P L Alagammai; Sukesh C Nair; Ian Mackie; Banumathi Ramakrishna; Jayaprakash Muliyil; Shyamkumar N Keshava; C E Eapen; Elwyn Elias
Journal:  Indian J Gastroenterol       Date:  2014-04-24

2.  Hepatobiliary quiz-12 (2014).

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12

3.  Noncirrhotic intrahepatic portal hypertension: towards a unifying definition and etiology.

Authors:  B S Ramakrishna
Journal:  Indian J Gastroenterol       Date:  2014-05-31

Review 4.  Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options.

Authors:  Ashish Goel; Joshua E Elias; Chundamannil E Eapen; Banumathi Ramakrishna; Elwyn Elias
Journal:  J Clin Exp Hepatol       Date:  2014-07-28

5.  Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.

Authors:  K S Prasanna; Ashish Goel; G Jayakumar Amirtharaj; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Uday Zachariah; K G Sajith; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-11-08

Review 6.  Idiopathic portal hypertension and extrahepatic portal venous obstruction.

Authors:  Rajeev Khanna; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2018-02-20       Impact factor: 6.047

7.  Investigation into celiac disease in Indian patients with portal hypertension.

Authors:  Rakhi Maiwall; Ashish Goel; Anna B Pulimood; Sudhir Babji; J Sophia; Chaya Prasad; K A Balasubramanian; Banumathi Ramakrishna; Susy Kurian; G John Fletcher; Priya Abraham; Gagandeep Kang; B S Ramakrishna; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2014-09-18

8.  Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis.

Authors:  Ashish Goel; Banumathi Ramakrishna; Jayaprakash Muliyil; Kadiyala Madhu; K G Sajith; Uday Zachariah; Jeyamani Ramachandran; Shyamkumar N Keshava; R Selvakumar; George M Chandy; Elwyn Elias; C E Eapen
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

9.  Arsenicosis, possibly from contaminated groundwater, associated with noncirrhotic intrahepatic portal hypertension.

Authors:  Ashish Goel; Pamela Christudoss; Renu George; Banumathi Ramakrishna; G Jayakumar Amirtharaj; Shyamkumar N Keshava; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Jude J Fleming; Elwyn Elias; Chundamannil E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-05-26

10.  ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.

Authors:  Ashish Goel; V Raghupathy; G J Amirtharaj; Aaron Chapla; Aparna Venkatraman; Banumathi Ramakrishna; Anup Ramachandran; Nihal Thomas; K A Balasubramanian; Ian Mackie; Elwyn Elias; Chundamannil E Eapen
Journal:  Indian J Gastroenterol       Date:  2017-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.